来源：Gangtise投研

　　巨子生物（02367.HK）2024年年度业绩发布会：公司2024年度业绩发布会展示了公司强劲的财务表现与业务进展。2024年公司收入达55.4亿元，同比增长57%，净利润20.6亿元，同比增长42%，净利率维持在37.2%的高水平。旗下两大核心品牌可复美与可丽金收入分别增长63%和36.3%，线上直销收入同比增长70%。公司计划派息12.4亿元，其中末期股息每股0.602亿元，特别股息每股0.592亿元。研发支出1.1亿元，同比增长42.1%，拥有188项在研项目和167项专利。可复美品牌收入45.4亿元，同比增长62.9%，可丽金品牌收入8.4亿元，同比增长36.3%。公司还积极推进重组胶原蛋白等技术的产业化，拓展线上线下的全渠道布局，并计划未来加大海外市场拓展与技术研发投入。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：王若云

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.